We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.26 EPS, expectations were $1.26. Operator: Good morning, and thank you ...

Abbott Laboratories, which makes the popular BinaxNow COVID-19 tests, expects significantly fewer sales of its COVID-19 tests in the fourth quarter compared with the rest of the year.

On the same day that United Airlines forecast stability, Abbott Labs warned investors to expect a $200 million hit.

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories reported $1 billion in fourth quarter profits despite an “expected year-over-year decline in Covid-19 testing-related sales,” the company said Wednesday.